SCHEMBL2804190

SCHEMBL2804190

NS(=O)(=O)c1ccccc1S(=O)(=O)NC(=O)c1cnc(Cl)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.50
PTGS1 P23219 3/20 0.41
PTGS2 P35354 3/20 0.41
P4HTM Q9NXG6 3/20 0.41
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
CA12 O43570 1/20 0.40
HDAC6 Q9UBN7 2/20 0.39
EGFR P00533 2/20 0.38
POLB P06746 1/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
KAT6A Q92794 2/20 0.38
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
ALKBH2 Q6NS38 1/20 0.37
ALKBH3 Q96Q83 1/20 0.37
FTO Q9C0B1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL977653 0.88 PTGES (0.52) PTGESPTGS1PTGS2P4HTMCA1
SCHEMBL979494 0.83 PTGES (0.55) PTGESPTGS1PTGS2P4HTMCA1
SCHEMBL979520 0.80 PTGES (0.46) PTGESPTGS1PTGS2P4HTMCA1
SCHEMBL2803062 0.79 EPHX2 (0.44) PTGESP4HTMCA1CA2CA9
SCHEMBL13065955 0.79 PTGES (0.46) PTGESHDAC6ALOX5APFEN1ALKBH2
SCHEMBL2807758 0.79 PTGES (0.48) PTGESPTGS1PTGS2P4HTMCA1
SCHEMBL13618615 0.78 BCAT1 (0.56) PTGESPTGS1PTGS2P4HTMCA1
SCHEMBL977428 0.78 PTGES (0.46) PTGESPTGS1PTGS2P4HTMCA1
SCHEMBL979817 0.78 PTGES (0.57) PTGESCA1CA2CA9HDAC6
SCHEMBL13631081 0.77 PTGES (0.51) PTGESPTGS1PTGS2P4HTMCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 PTGES 9/4885PTGS1 4/4885PTGS2 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.